TLI: Pioneering Research
The physicians of The Texas Liver Institute are professors of medicine at The Texas Health Science Center and involved with the teaching programs of fellows and residents. The Institute is also home to preceptorships and clinical residencies for health care providers and allied health professionals from all over the world.
The Texas Liver Institute is led by globally recognized hepatologists who have published more than 500 papers and book chapters. Our academic pursuits focus on cutting-edge innovative research.
Our research staff is composed of an expert staff and departments comprised of experienced Sub Investigators, Research Department Directors, Site Start Up Specialist, Quality Assurance, Contracts and Finance, ACRP certified Coordinators, Patient Recruitment and Pharmacy Technicians. With over 80 skilled healthcare providers and staff we ensure the highest quality of care is delivered to our patients.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir.
Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. We assessed the efficacy and safety of an interferon-free regimen—a fixed-dose combination of the nucleotide polymerase inhibitor sofosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and without ribavirin—in patients with genotype-1 hepatitis C infection who were treatment-naive or previously treated with a protease-inhibitor regimen.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and efficacy of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-naive, patients with HCV.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive patients with genotype 1—3 HCV infection.
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
An estimated 184 million people worldwide have hepatitis C virus (HCV) infection, a leading cause of chronic liver disease and the leading indication for liver transplantation globally. Approximately 25% of persons with HCV infection in the United States have cirrhosis, and this number is expected…
Treatment of HCV Infection by Targeting MicroRNA
Approximately 170 million persons worldwide are chronically infected with the hepatitis C virus (HCV). Chronic HCV infection is a major cause of liver cirrhosis, liver failure, and hepatocellular carcinoma and is the leading indication for liver transplantation in many Western countries. Sustained…
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver cancer, and liver transplantation. Peginterferon-free regimens of direct-acting antiviral agents have the potential to improve both the safety and efficacy of HCV therapy, as compared with the current standard treatment of…
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
As many as 170 million persons are chronically infected with the hepatitis C virus (HCV) worldwide, and more than 350,000 die annually from liver disease caused by HCV. Estimates of the number of persons in the United States who have chronic HCV infection range from 2.7 million to 5.2 million. For…
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
More than 3 million people in the United States are chronically infected with the hepatitis C virus (HCV). Although the number of new infections has been declining for decades, HCV-related morbidity and mortality are projected to continue rising for another 20 years. One half to three quarters of…
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Among the estimated 170 million people in the world who have chronic hepatitis C virus (HCV) infection, approximately 60% have the genotype 1 strain of the virus. The treatment of patients infected with HCV genotype 1 is evolving rapidly.– At the end of 2013, the Food and Drug Administration (FDA)…
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Chronic infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide and is a major cause of cirrhosis and hepatocellular carcinoma. HCV-related morbidity and mortality are increasing; since 2007, HCV-related deaths in the United States have exceeded those from human…
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver cancer, and end-stage liver disease. The current standard of care for chronic HCV genotype 1 infection is pegylated interferon (peginterferon) and ribavirin, with a protease inhibitor (boceprevir or telaprevir).…
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
When studied in clinical trials, the current standard-of-care therapy for patients with hepatitis C virus (HCV) genotype 2 or 3 infection — pegylated interferon in combination with ribavirin for 24 weeks — resulted in a sustained virologic response in 70 to 85% of patients who had not received…
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver cancer, and liver transplantation. Peginterferon-free regimens of direct-acting antiviral agents have the potential to improve both the safety and efficacy of HCV therapy, as compared with the current standard treatment of…
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), including 4.1 million in the United States. HCV infection is the most common cause of chronic liver disease in the United States and a leading cause of cirrhosis and hepatocellular carcinoma globally. HCV is…
Telaprevir for Retreatment of HCV Infection
Approximately 60% of patients who are infected with hepatitis C virus (HCV) genotype 1 are not cured by 48 weeks of peginterferon alfa combined with ribavirin. Such patients fall into one of three categories: those who have no response to therapy, which is defined as a reduction of less than 2…
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
More than 170 million people are chronically infected with hepatitis C virus (HCV) worldwide. The standard treatment is combination therapy with peginterferon and ribavirin.– Of the six HCV genotypes, genotype 1 is the least responsive to currently approved therapies, with rates of sustained…
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
Hepatitis C virus (HCV) chronically infects approximately 180 million people worldwide and is a frequent cause of liver disease, including liver failure and hepatocellular carcinoma. HCV treatment is recommended for persons at the greatest risk for progression of liver disease. On the basis of…